Population
In vitro rhinovirus (100 serotypes) and enterovirus (16 serotypes)
Comparison
Pirodavir (R 77975) vs R 61837 (predecessor compound)
Design
Preclinical
Authors
Loading...
Supports preclinical development of capsid binders; leaves open translation to clinical efficacy in humans.
Pirodavir is a novel capsid-binding antipicornavirus agent with potent in vitro activity against both group A and group B rhinovirus serotypes.
Andries et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: